Project Grant R44EY038605
- The National Eye Institute awarded Aeon Imaging LLC $311,748 on August 15, 2026, under the Vision Research program (CFDA 93.867) to design, build, and demonstrate a more accurate visual acuity test device that corrects for optical artifacts common in aging eyes while remaining cost-competitive with electronic VA tests. Current visual acuity measurements in older patients are compromised by uncontrolled pupil size, retinal illuminance, wavefront aberrations, wide-field glare, and crowding...
- The National Eye Institute awarded The Schepens Eye Research Institute $858,394 on August 1, 2026, under the Vision Research program (CFDA 93.867) to develop multimodal foundation models for eye disease screening and prognosis. The research develops a vision-language foundation model trained on pairs of retinal images and clinical notes to enable downstream supervised models for detection and progression prediction of age-related macular degeneration, diabetic retinopathy, and glaucoma. The...
- The National Eye Institute awarded $753,787 to The General Hospital Corporation (doing business as Massachusetts General Hospital) on August 1, 2026, under the Vision Research program (CFDA 93.867) to develop low-cost ultra-widefield retinal optical coherence tomography (OCT) technology based on photonic-electronic integration. The project addresses cost barriers that limit clinical availability of OCT instrumentation used to detect and monitor diabetic retinopathy, age-related macular...
- The National Eye Institute awarded Perzeption Inc. $305,406 on September 1, 2026, under the Vision Research program (CFDA 93.867) to develop and evaluate an efficient photostress recovery assessment method for age-related macular degeneration. The project addresses the need for sensitive functional biomarkers to detect early-stage AMD and measure disease progression or treatment response. Perzeption will develop a novel, personalized, adaptive testing method to assess photostress recovery in...
- The National Eye Institute of the Department of Health and Human Services awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $723,931 on August 15, 2026, under the Vision Research program (CFDA 93.867). The award funds functional characterization of lateral geniculate nucleus (LGN) microstimulation as an advanced artificial vision system. The research validates a novel 1000-channel electrode array called the Fountain Probe, engineered for volumetric...
- The National Eye Institute awarded Massachusetts Eye and Ear Infirmary $467,277 on July 1, 2026, under the Vision Research program (CFDA 93.867) to develop and validate a clinical neuropsychological assessment battery combined with mobile eye tracking to characterize the visuoperceptual profile of cerebral visual impairment. The testing battery comprises five standardized neuropsychological assessments focused on evaluating visual scanning, planning, processing speed, and visuomotor...
- The National Eye Institute awarded Neurofieldz Inc. $375,940 on September 15, 2025, under the Vision Research program (CFDA 93.867) to develop and validate a portable wireless diagnostic system for optic neuropathies and other diseases of the afferent visual system. Neurofieldz will conduct a Phase I Small Business Innovation Research feasibility study to advance NeuroVEP, a breakthrough sensor system that measures visual evoked potentials at the visual cortex using electric field...
- The National Eye Institute awarded The New England College of Optometry $371,997 on June 1, 2026, under the Vision Research program (CFDA 93.867) to test a novel emmetropization mechanism model based on spectral and spatial opponent information in young children with myopia. The project will investigate how the retina controls eye growth and refraction through a blue-versus-yellow spectral-opponent mechanism. The research tests whether imbalances in retinal spectral and spatial...
- Federal Grant Award Summary The National Eye Institute (NEI) awarded a $421,136 Project Grant to the University of Maryland, College Park, effective August 1, 2025, through July 31, 2027, under the Vision Research program (CFDA 93.867). This award supports research into advanced wavefront shaping techniques designed to enable high-resolution fundus imaging in patients with ocular opacities—conditions affecting the cornea and lens that currently prevent effective posterior segment eye...
- The National Eye Institute awarded Oregon Health & Science University $498,180 on September 1, 2026, under the Vision Research program (CFDA 93.867) to develop and apply novel optical coherence tomography (OCT) methods for detecting and monitoring photoreceptor changes associated with age-related macular degeneration. The project runs through August 31, 2030, with performance based in Portland, Oregon. Aim 1 investigates cone photoreceptor function impairments in AMD through advancement of...
The National Eye Institute awarded Nanoscope Instruments, Inc., $1,019,678 on September 1, 2026, under the Vision Research program (CFDA 93.867) to develop and validate the Multi-Luminance Shape Discrimination Test, a device that measures functional vision in patients with moderate to severe vision loss. The recipient will evaluate the retest variability and performance of the Multi-Luminance Shape Discrimination Test in patients with geographic atrophy, wet age-related macular degeneration, retinal vein occlusion, or diabetic macula edema. Work includes mapping the inter-relationship of size and luminance scores across different visual acuity cohorts to streamline testing protocols, validating the system through correlative measurements with Early Treatment Diabetic Retinopathy Study charts and visual field testing, and establishing the clinical meaningfulness of measured changes. The Multi-Luminance Shape Discrimination Test addresses a gap in traditional vision assessment by capturing real-world visual capabilities—contrast sensitivity, object recognition, and mobility—rather than relying solely on best-corrected visual acuity. Prior observational and interventional trials have demonstrated that shifts of two or more luminance levels on the test correlate with improved independence and daily functioning in patients, and the device has shown promise in evaluating the impact of investigational therapies. Performance takes place in Bedford, Texas. The award period runs through June 30, 2028. This is a Project Grant, an assistance type supporting defined, time-limited research initiatives.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $1.0m | 8/19/26 |